SHENZHEN, China, July 25, 2024 /PRNewswire/ -- SIBIONICS, a
leading innovator in continuous glucose monitoring technology,
announced today that it has received Product Marketing
Authorization Approval from the Ministry of Health and
Prevention (MoHAP) for its GS1 Continuous Glucose Monitoring
(CGM) System in the UAE. This allows SIBIONICS to
officially introduce its GS1 CGM System to the UAE market, marking
a significant milestone in SIBIONICS' global expansion
strategy.
The MoHAP approval underscores SIBIONICS' commitment to
delivering cutting-edge CGM technologies that meet rigorous safety
and efficacy standards. This fingerstick-free, factory-calibrated,
and scanning-free CGM system, renowned for its low MARD value of
8.83% and user-friendly design, offers diabetes patients and
healthcare professionals an advanced solution for continuous
glucose monitoring. The GS1 provides real-time glucose data for 14
days, customizable glucose alarm, seamless data-sharing, and
exportable in-app AGP report. These crucial features can help
optimize treatment plans and significantly enhance patient
outcomes.
In conjunction with this approval,
SIBIONICS also announced a strategic partnership
with Pharmaworld Store as their exclusive distributor for the GS1
CGM System in the UAE. This collaboration will leverage Pharmaworld
Store's extensive distribution network and market expertise to
ensure that the GS1 CGM System reaches healthcare providers and
patients across the region effectively.
"This approval from MoHAP is a testament to the quality and
reliability of our GS1 CGM," said Patrick
Nowlin, Chief Global Strategy Officer of SIBIONICS. "We
are thrilled to partner with Pharmaworld Store, whose deep
understanding of the UAE healthcare market will be instrumental in
bringing the GS1 to patients who need it most."
The introduction of the GS1 CGM System, backed by Pharmaworld
Store's strong distribution capabilities, matches UAE's vision of
integrating innovative medical technologies to enhance the overall
quality of healthcare services. SIBIONICS' entry into the UAE
market, in partnership with Pharmaworld Store, is expected to help
facilitate diabetes care and improve the quality of life for
patients across the region.
About SIBIONICS
Founded in 2015, SIBIONICS is at the forefront of R&D and
the commercialization of implantable medical devices. By merging
state-of-the-art CGM technology with user-centric designs,
SIBIONICS is redefining the possibilities in personalized diabetes
management solutions. To date, SIBIONICS has partnered with over
2,600 health facilities, successfully integrating the GS1 CGM
System into inpatient treatment and benefiting more than 1.2
million users across 50+ countries worldwide.
For more information about SIBIONICS, please
visit www.sibionicscgm.com.
About Pharmaworld Store
Pharmaworld Store, a premier healthcare distributor, boasts a
diverse portfolio that includes pharmaceuticals, medical devices,
and health and wellness solutions. The company has earned a stellar
reputation for excellence and reliability, ensuring that healthcare
providers and patients have access to the latest and most effective
medical technologies.
For inquiries or purchases of the SIBIONICS GS1 CGM in the UAE,
please reach out to Pharmaworld Store at +971 4 294 2039.
Photo -
https://mma.prnewswire.com/media/2468928/SIBIONICS_Secures_MoHAP_Product_Marketing_Authorization_Approval_Its_GS1_CGM.jpg
Logo -
https://mma.prnewswire.com/media/2263484/logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sibionics-secures-mohap-product-marketing-authorization-approval-for-its-gs1-cgm-in-uae-302206367.html